How will process development and analytical innovation drive growth for the future of cell and gene therapies?

We are at a critical inflection point for commercialization as more cell and gene therapies (CGTs) enter clinical trials. However, developing CGTs presents unique complexities, such as variable production methods and analytical challenges. This article explores strategies for addressing these challenges through standardization and scalability. These include platforms that reduce hands-on time and cost of goods (COGs) in cell therapy, as well as 3D suspension-based approaches and perfusion technologies for improving viral vector and exosome production. These innovations aim to streamline manufacturing and support the broader adoption of advanced therapeutics.